Curative Biotechnology Company Description
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications.
It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor.
The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine.
Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | I. Garr |
Contact Details
Address: 3801 PGA Blvd Palm Beach Gardens, Florida 33410 United States | |
| Phone | 561 907 8990 |
| Website | curativebiotech.com |
Stock Details
| Ticker Symbol | CUBT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US23128N1081 |
| SIC Code | 6719 |
Key Executives
| Name | Position |
|---|---|
| I. Richard Garr Esq., J.D. | Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and General Counsel |
| Paul M. Michaels | President and Executive Chairman |
| Pam Bisikirski | Vice President of Communications |
| Dr. Ronald Bordens Ph.D. | Executive Vice President of Process Product Drug Development and Member of Scientific and Clinical Advisory Board |